• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

乳腺癌中HER2表达与其他预后因素的相关性:与Ki-67指数和P53状态呈负相关。

Correlations between HER2 Expression and Other Prognostic Factors in Breast Cancer: Inverse Relations with the Ki-67 Index and P53 Status.

作者信息

Payandeh Mehrdad, Shahriari-Ahmadi Ali, Sadeghi Masoud, Sadeghi Edris

机构信息

Cancer Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran E-mail :

出版信息

Asian Pac J Cancer Prev. 2016;17(3):1015-8. doi: 10.7314/apjcp.2016.17.3.1015.

DOI:10.7314/apjcp.2016.17.3.1015
PMID:27039719
Abstract

BACKGROUND

Overexpression or amplification of human epidermal growth factor receptor-2 (HER2) is associated with grade of malignancy and a poor prognosis in breast cancer (BC). The aim of this study was to evaluate of value of HER2 as a prognostic marker, and to analyze associations with common histopathological parameters in BC cases.

MATERIALS AND METHODS

Between of 2007 to 2014, 260 patients with BC referred to Oncology Clinic provided cancer tissue samples which underwent immunohistochemistry (IHC) for markers. ER and PR positivity was defined as ≥10% positive tumor cells with nuclear staining. HER2-positive was defined as either HER2 gene amplification by fluorescent in situ hybridization (FISH) or scored as 3+ by IHC. For HER2 (2+), FISH was performed to determine HER2 positivity.

RESULTS

The mean age at diagnosis for the patients with HER2-negative was significantly higher than in HER2-positive cases. Also, there were significant correlations between histological grade, nuclear grade, lymph node metastasis, tumor size, ER status, PR status, p53 overexpression and Ki-67 index with HER2 expression. HER2-negative lesions were of higher grade and more likely to be ER-negative, PR-negative, p53-positive, lymph node metastasis, with a tumor size<2cm and also Ki-67≥20% as compared to the HER2-positive group.

CONCLUSIONS

Contrary to the results of other studies, HER2-positive tumors in our study had a lower Ki-67 index and were p53-positive. Also, Ki-67 proliferation index ≥20% in more studies was associated with p53-positive.Therefore, tumors which are HER2-positive and have a Ki-67≥20% had a more aggressive behavior compared to HER2-positive and Ki-67<20% lesions.

摘要

背景

人表皮生长因子受体2(HER2)的过表达或扩增与乳腺癌(BC)的恶性程度及不良预后相关。本研究旨在评估HER2作为预后标志物的价值,并分析其与BC病例常见组织病理学参数的相关性。

材料与方法

2007年至2014年间,260例转诊至肿瘤诊所的BC患者提供了癌组织样本,这些样本接受了标志物的免疫组织化学(IHC)检测。雌激素受体(ER)和孕激素受体(PR)阳性定义为核染色阳性肿瘤细胞≥10%。HER2阳性定义为通过荧光原位杂交(FISH)检测HER2基因扩增或IHC评分为3+。对于HER2(2+),进行FISH检测以确定HER2阳性。

结果

HER2阴性患者的诊断时平均年龄显著高于HER2阳性病例。此外,组织学分级、核分级、淋巴结转移、肿瘤大小、ER状态、PR状态、p53过表达和Ki-67指数与HER2表达之间存在显著相关性。与HER2阳性组相比,HER2阴性病变分级更高,更可能为ER阴性、PR阴性、p53阳性、有淋巴结转移,肿瘤大小<2cm且Ki-67≥20%。

结论

与其他研究结果相反,本研究中HER2阳性肿瘤的Ki-67指数较低且p53阳性。此外,在更多研究中Ki-67增殖指数≥20%与p53阳性相关。因此,与HER2阳性且Ki-67<20%的病变相比,HER2阳性且Ki-67≥20%的肿瘤行为更具侵袭性。

相似文献

1
Correlations between HER2 Expression and Other Prognostic Factors in Breast Cancer: Inverse Relations with the Ki-67 Index and P53 Status.乳腺癌中HER2表达与其他预后因素的相关性:与Ki-67指数和P53状态呈负相关。
Asian Pac J Cancer Prev. 2016;17(3):1015-8. doi: 10.7314/apjcp.2016.17.3.1015.
2
Interrelationships Between Ki67, HER2/neu, p53, ER, and PR Status and Their Associations With Tumor Grade and Lymph Node Involvement in Breast Carcinoma Subtypes: Retrospective-Observational Analytical Study.乳腺癌亚型中Ki67、HER2/neu、p53、雌激素受体(ER)和孕激素受体(PR)状态之间的相互关系及其与肿瘤分级和淋巴结受累的关联:回顾性观察分析研究
Medicine (Baltimore). 2015 Aug;94(32):e1359. doi: 10.1097/MD.0000000000001359.
3
Differential amplification and overexpression of HER-2/neu, p53, MIB1, and estrogen receptor/progesterone receptor among medullary carcinoma, atypical medullary carcinoma, and high-grade invasive ductal carcinoma of breast.乳腺髓样癌、非典型髓样癌及高级别浸润性导管癌中HER-2/neu、p53、MIB1以及雌激素受体/孕激素受体的差异扩增与过表达。
Arch Pathol Lab Med. 2003 Nov;127(11):1458-64. doi: 10.5858/2003-127-1458-DAAOON.
4
Assessing the impact of polysomy-17 on HER2 status and the correlations of HER2 status with prognostic variables (ER, PR, p53, Ki-67) in epithelial ovarian cancer: a tissue microarray study using immunohistochemistry and fluorescent in situ hybridization.评估 17 号染色体三体对 HER2 状态的影响,以及 HER2 状态与上皮性卵巢癌中预后变量(ER、PR、p53、Ki-67)的相关性:应用免疫组化和荧光原位杂交的组织微阵列研究。
Int J Gynecol Pathol. 2011 Jul;30(4):372-9. doi: 10.1097/PGP.0b013e31820c9ff3.
5
Study of ER, PR, HER2/neu, p53, and Ki67 expression in primary breast carcinomas and synchronous metastatic axillary lymph nodes.原发性乳腺癌及同步转移腋窝淋巴结中雌激素受体(ER)、孕激素受体(PR)、人表皮生长因子受体2(HER2/neu)、p53和Ki67表达的研究
Indian J Cancer. 2020 Apr-Jun;57(2):190-197. doi: 10.4103/ijc.IJC_610_18.
6
Correlation of proliferative index with various clinicopathologic prognostic parameters in primary breast carcinoma: A study from North India.原发性乳腺癌增殖指数与各种临床病理预后参数的相关性:一项来自印度北部的研究。
J Cancer Res Ther. 2018 Apr-Jun;14(3):537-542. doi: 10.4103/0973-1482.167614.
7
Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer.荧光原位杂交技术在确定乳腺癌HER2基因扩增中的预后效用
Oncol Rep. 2008 Mar;19(3):651-6.
8
Estrogen receptor-negative and human epidermal growth factor receptor 2-negative breast cancer tissue have the highest Ki-67 labeling index and EGFR expression: gene amplification does not contribute to EGFR expression.雌激素受体阴性和人表皮生长因子受体2阴性的乳腺癌组织具有最高的Ki-67标记指数和表皮生长因子受体(EGFR)表达:基因扩增对EGFR表达无影响。
Oncol Rep. 2005 Aug;14(2):337-43.
9
Tumour biomarker expression relative to age and molecular subtypes of invasive breast cancer.肿瘤生物标志物的表达与浸润性乳腺癌的年龄和分子亚型相关。
Br J Cancer. 2012 Jul 10;107(2):382-7. doi: 10.1038/bjc.2012.219. Epub 2012 Jun 19.
10
MYC amplification in subtypes of breast cancers in African American women.非洲裔美国女性乳腺癌亚型中的 MYC 扩增。
BMC Cancer. 2018 Mar 9;18(1):274. doi: 10.1186/s12885-018-4171-6.

引用本文的文献

1
Moonlight human ribosomal protein L13a downregulation is associated with p53 and HER2/neu expression in breast cancer.月光下人类核糖体蛋白 L13a 的下调与乳腺癌中 p53 和 HER2/neu 的表达有关。
J Appl Biomed. 2020 Aug;18(2-3):46-53. doi: 10.32725/jab.2020.008. Epub 2020 Jun 17.
2
HER2 overexpression and correlation with other significant clinicopathologic parameters in Ivorian breast cancer women.科特迪瓦乳腺癌女性中HER2过表达及其与其他重要临床病理参数的相关性
BMC Clin Pathol. 2019 Jan 17;19:1. doi: 10.1186/s12907-018-0081-4. eCollection 2019.
3
Limited utility of tissue micro-arrays in detecting intra-tumoral heterogeneity in stem cell characteristics and tumor progression markers in breast cancer.
组织微阵列在检测乳腺癌干细胞特征和肿瘤进展标志物的肿瘤内异质性方面的应用有限。
J Transl Med. 2018 May 8;16(1):118. doi: 10.1186/s12967-018-1495-6.
4
Correlation of Immunohistochemistry and Fluorescence Hybridization for HER-2 Assessment in Breast Cancer Patients: Single Centre Experience.免疫组织化学与荧光杂交技术在乳腺癌患者HER-2评估中的相关性:单中心经验
Open Access Maced J Med Sci. 2018 Mar 23;6(4):593-599. doi: 10.3889/oamjms.2018.124. eCollection 2018 Apr 15.
5
Is There any Concordance between of IHC with FISH in HER2-Positive Breast Cancer Patients?在HER2阳性乳腺癌患者中,免疫组化(IHC)与荧光原位杂交(FISH)结果之间是否存在一致性?
Int J Hematol Oncol Stem Cell Res. 2017 Jan 1;11(1):43-48.